ESEhud Shahar

Ehud Shahar

*This is an algorithmically generated author record based on publicly available information.

Ehud Shahar has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Viruses of avian origin demonstrate potential for cancer virotherapy

    by Jacob Pitcovski, Gilad Gallili, Daria Oren Aharon, Shir Malka, Gal Yanovich, Elad Milrot, Ehud Shahar

  • Open Access

    Protection Against Salmonella by Vaccination with Toxin–Antitoxin Self-Destructive Bacteria

    by Nady Gruzdev, Jacob Pitcovski, Chen Katz, Nili Ruimi, Dalia Eliahu, Caroline Noach, Ella Rosenzweig, Avner Finger, Ehud Shahar

    Background: Salmonella is a major zoonotic foodborne pathogen. Conventional poultry vaccines may present limitations in terms of efficacy, safety, and practicality. Objectives: This study focuses on enhancing the immunogenicity and improving the safety of a novel oral vaccination employing inducible toxin–antitoxin (TA) systems, which lead to self-destruction of virulent Salmonella Enteritidis. Methods: A Hok/Sok (HS) TA system was designed to induce cell death upon absence of arabinose. Point mutations were introduced to the Hok toxin promoter to moderate toxin production. A combination of HS and CeaB/CeiB (CC) TA systems was designed to induce cell death both in low di-cation levels or anaerobic conditions. Survival of Salmonella-carrying TA systems was tested in culture and in the Raw264.7 macrophage cell line. One-day old chicks were inoculated with Salmonella carrying the TA system to evaluate bacterial persistence and induction of a protective immune response. Results: Attenuation of the Hok toxin promoter prolonged bacterial survival in vitro. Salmonella carrying the combined TA systems was eliminated completely both in vitro and in inoculated chickens, eliciting high levels of antibodies and conferring protection against challenge with wild-type Salmonella. Conclusions: These findings highlight the potential of the adaptable TA-based vaccination platform to generate safe and efficacious Salmonella vaccines for poultry, contributing to reduced transmission in the food chain.


  • Open Access

    Viruses of Avian Origin for Cancer Virotherapy

    by Jacob Pitcovski Pitcovski, Gilad Gallili, Daria Oren Aharon, Shir Malka, Gal Yanovich, Elad Milrot, Ehud Shahar

    Oncolytic viruses (OVs) can selectively infect and kill tumor cells. Although showing promise, several challenges impede OVs broad application in cancer therapy. A major obstacle is limited treatment duration due to preexisting or the induction of neutralizing immune responses toward the OVs following treatment. Widening the reservoir of OVs will allow replacement of treatment viruses following neutralization. This study aimed to identify new OVs and to test their oncolytic effect. Eight avian viruses (AVs) were used to infect human and mice normal and cancerous cell lines, of which three displayed superior ability to selectively kill cancer cells in vitro. These AVs induced cytopathic effects and inhibited proliferation of fifteen out of eighteen cancer cell lines tested, each affecting 5–14 of the cell lines; none affected normal fibroblasts. In vivo , growth of G361 melanoma cell tumors in nude mice was inhibited following intra-tumoral (i.t) injection of AVs. In two models of immunocompetent mice carrying tumors and injected i.t with AVs, tumors growth was significantly delayed. Albeit tumor growth commenced in correlation with the development of anti-virus antibody levels. These tested AVs together with their field-characterized variants, comprise a vast arsenal of potential OVs that may open the possibility of administration of several viruses in mix or in sequence to overcome both tumor resistance due to acquired mutations as well as neutralization by the rise of the acquired immune response. In conclusion, the AVs tested in this study demonstrated OVs characteristics and may be used to enable prolonged cancer virotherapy treatment.

  • Open Access

    Plant-Derived Epi-Nutraceuticals as Potential Broad-Spectrum Anti-Viral Agents

    by Rosita Gabbianelli, Ehud Shahar, Gaia de Simone, Chiara Rucci, Laura Bordoni, Giulia Feliziani, Fanrui Zhao, Marta Ferrati, Filippo Maggi, Eleonora Spinozzi, et al.

    Although the COVID-19 pandemic appears to be diminishing, the emergence of SARS-CoV-2 variants represents a threat to humans due to their inherent transmissibility, immunological evasion, virulence, and invulnerability to existing therapies. The COVID-19 pandemic affected more than 500 million people and caused over 6 million deaths. Vaccines are essential, but in circumstances in which vaccination is not accessible or in individuals with compromised immune systems, drugs can provide additional protection. Targeting host signaling pathways is recommended due to their genomic stability and resistance barriers. Moreover, targeting host factors allows us to develop compounds that are effective against different viral variants as well as against newly emerging virus strains. In recent years, the globe has experienced climate change, which may contribute to the emergence and spread of infectious diseases through a variety of factors. Warmer temperatures and changing precipitation patterns can increase the geographic range of disease-carrying vectors, increasing the risk of diseases spreading to new areas. Climate change may also affect vector behavior, leading to a longer breeding season and more breeding sites for disease vectors. Climate change may also disrupt ecosystems, bringing humans closer to wildlife that transmits zoonotic diseases. All the above factors may accelerate the emergence of new viral epidemics. Plant-derived products, which have been used in traditional medicine for treating pathological conditions, offer structurally novel therapeutic compounds, including those with anti-viral activity. In addition, plant-derived bioactive substances might serve as the ideal basis for developing sustainable/efficient/cost-effective anti-viral alternatives. Interest in herbal antiviral products has increased. More than 50% of approved drugs originate from herbal sources. Plant-derived compounds offer diverse structures and bioactive molecules that are candidates for new drug development. Combining these therapies with conventional drugs could improve patient outcomes. Epigenetics modifications in the genome can affect gene expression without altering DNA sequences. Host cells can use epigenetic gene regulation as a mechanism to silence incoming viral DNA molecules, while viruses recruit cellular epitranscriptomic (covalent modifications of RNAs) modifiers to increase the translational efficiency and transcript stability of viral transcripts to enhance viral gene expression and replication. Moreover, viruses manipulate host cells’ epigenetic machinery to ensure productive viral infections. Environmental factors, such as natural products, may influence epigenetic modifications. In this review, we explore the potential of plant-derived substances as epigenetic modifiers for broad-spectrum anti-viral activity, reviewing their modulation processes and anti-viral effects on DNA and RNA viruses, as well as addressing future research objectives in this rapidly emerging field.


  • Open Access

    Plant-derived epi-nutraceuticals as Potential Broad-Spectrum Anti-Viral Agents

    by Rosita Gabbianelli, Ehud Shahar, Gaia De Simone, Chiara Rucci, Laura Bordoni, Giulia Feliziani, Fanrui Zhao, Marta Ferrati, Filippo Maggi, Eleonora Spinozzi, et al.

    Although the COVID-19 pandemic appears to be diminishing, the emergence of SARS-CoV-2 variants represents a threat to humans due to its inherent transmissibility, immunological evasion, virulence, and invulnerability to existing therapies. The previous COVID-19 pandemic affected more than 500 million people and caused over 6 million deaths. Vaccines are essential, but in circumstances when vaccination is not accessible or in individuals with compromised immune systems, drugs can give additional protection. Targeting host signaling pathways is recommended due to their genomic stability and resistance barriers. Plant-derived products, which have been used in traditional medicine for treating pathological conditions, offer structurally novel therapeutic compounds including anti-viral. In addition, plant-derived bioactive substances might serve as the ideal basis for developing sustainable/efficient/cost-effective anti-viral alternatives. Epigenetic modifications in the genome can affect gene expression without altering DNA sequence. Host cells can use epigenetic gene regulation as a mechanism to silence incoming viral DNA molecules, while viruses have recruited cellular epi transcriptomic (covalent modifications of RNAs) modifiers to increase the translational efficiency and transcript stability of viral transcripts to enhance viral gene expression and replication. Moreover, viruses manipulate host cells' epigenetic machinery to ensure productive viral infections. Environmental factors, such as natural products, may influence epigenetic modifications. In this review, we are exploring the potential of plant-derived substances as epigenetic modifiers for broad-spectrum anti-viral activity, reviewing modulation processes and anti-viral effects on DNA and RNA viruses, and addressing future research objectives in this rapidly emerging field.


  • Development of toxin-antitoxin self-destructive bacteria, aimed for salmonella vaccination

    by Nady Gruzdev, Jacob Pitcovski, Chen Katz, Nili Ruimi, Dalia Eliahu, Caroline Noach, Ella Rosenzweig, Avner Finger, Ehud Shahar


  • Endotoxin-free gram-negative bacterium as a system for production and secretion of recombinant proteins

    by Ehud Shahar, Ken Emquies, Itai Bloch, Dalia Eliahu, Ran Ben Adiva, Jacob Pitcovski, Itamar Yadid

    Gram-negative bacteria are common and efficient protein expression systems, yet their outer membrane endotoxins can elicit undesirable toxic effects, limit


  • Open Access

    Production and secretion of recombinant proteins using the endotoxin-free, Gram-negative bacterium Sphingobium japonicum

    by Ehud Shahar, Ken Emquies, Jacob Pitcovski, Itai Bloch, Dalia Eliahu, Ran Ben Adiva, Itamar Yadid

    Gram-negative bacteria are common and efficient protein expression systems, yet their outer membrane endotoxins can elicit undesirable toxic effects, limiting their applicability for parenteral therapeutic applications, e.g., production of vaccine components. In the bacterial genus Sphingomonas from the Alphaproteobacteria class, lipopolysaccharide (LPS) endotoxins are replaced with non-toxic glycosphingolipids (GSL), rendering it an attractive alternative for therapeutic protein production. To explore the use of Sphingomonas as a safe expression system for production of proteins for therapeutic applications, in this study, Sphingobium japonicum ( SJ ) injected live into embryonated hen eggs proved safe and nontoxic. Multimeric viral polypeptides derived from Newcastle disease virus (NDV) designed for expression in SJ, yielded soluble proteins which were specifically recognized by antibodies raised against the whole virus. In addition, native signal peptides (SP) motifs identified using whole-genome computerized analysis and coupled to secreted proteins in SJ induced secretion of αAmy and mCherry gene products. Relative to the same genes expressed without an SP, SP 104 increased secretion of αAmy (3.7-fold) and mCherry (16.3-fold) proteins and yielded accumulation of up to 80µg/L of the later in the culture medium. Taken together, the presented findings demonstrate the potential of this unique LPS-free Gram-negative bacterial family to serve as an important tool for protein expression for both research and biotechnological purposes, including for the development of novel vaccines. Importance: The Gram-negative, LPS-free Sphingomonas genus can serve as an effective and safe platform for therapeutic protein expression and secretion and bears potential as a live bacteria delivery system for protein vaccines.


  • Open Access

    Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine

    by Jacob Pitcovski, Nady Gruzdev, Anna Abzach, Chen Katz, Ran Ben-Adiva, Michal Brand-Shwartz, Itamar Yadid, Einav Ratzon-Ashkenazi, Ken Emquies, Hadasa Israeli, et al.


  • Protection against avian coronavirus conferred by oral vaccination with live bacteria secreting LTB-fused viral proteins

    by Avishai Lublin, Chen Katz, Nady Gruzdev, Itamar Yadid, Itai Bloch, Yigal Farnoushi, Luba Simanov, Asaf Berkowitz, Dalia Elyahu, Jacob Pitcovski, et al.